As first-line therapy for advanced renal cell carcinoma, nivolumab plus cabozantinib prolongs progression-free survival compared with sunitinib in patients with and without a prior nephrectomy.
Researchers found preoperative blood glucose levels were associated with hospital length of stay for patients undergoing laparoscopic nephrectomy for RCC.
Men nearly always outnumbered women, regardless of trial phase, cancer type, time period, or cancer incidence in the female population.
Rate of disease-free survival at 24 months higher with pembrolizumab versus placebo following nephrectomy.
The approval was based on data from an open-label phase 2 study which evaluated the efficacy and safety of Welireg in patients with von Hippel-Lindau-associated renal cell carcinoma and other VHL-associated tumors.
The approval was based on data from the pivotal phase 3 CLEAR (Study 307)/KEYNOTE-581 trial.
Treatment-naïve patients had better outcomes than previously-treated patients.
Decisions of how to proceed when positive surgical margins are found after partial nephrectomy are left to the discretion of the surgeon.
Ideal patient selection for a deferred cytoreductive nephrectomy should include an assessment of Memorial Sloan Kettering Cancer Center risk score, according to investigators.
A retrospective study identified factors that influenced overtreatment and undertreatment among patients with kidney cancer.
